NO20041908L - Anvendelse av gpl30 aktivatorer ved diabetisk neuropati - Google Patents

Anvendelse av gpl30 aktivatorer ved diabetisk neuropati

Info

Publication number
NO20041908L
NO20041908L NO20041908A NO20041908A NO20041908L NO 20041908 L NO20041908 L NO 20041908L NO 20041908 A NO20041908 A NO 20041908A NO 20041908 A NO20041908 A NO 20041908A NO 20041908 L NO20041908 L NO 20041908L
Authority
NO
Norway
Prior art keywords
diabetic neuropathy
activators
medicament
prevention
manufacture
Prior art date
Application number
NO20041908A
Other languages
English (en)
Norwegian (no)
Inventor
Michel Dreano
Pierre-Alain Vitte
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20041908L publication Critical patent/NO20041908L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20041908A 2001-10-11 2004-05-10 Anvendelse av gpl30 aktivatorer ved diabetisk neuropati NO20041908L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01123400 2001-10-11
PCT/EP2002/011364 WO2003033015A1 (en) 2001-10-11 2002-10-10 USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY

Publications (1)

Publication Number Publication Date
NO20041908L true NO20041908L (no) 2004-05-10

Family

ID=8178778

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041908A NO20041908L (no) 2001-10-11 2004-05-10 Anvendelse av gpl30 aktivatorer ved diabetisk neuropati

Country Status (20)

Country Link
US (3) US7465441B2 (sh)
EP (1) EP1434597B1 (sh)
JP (1) JP2005505608A (sh)
KR (1) KR20050035151A (sh)
CN (1) CN1602203A (sh)
AT (1) ATE542542T1 (sh)
AU (1) AU2002340547B2 (sh)
BR (1) BR0213183A (sh)
CA (1) CA2463020A1 (sh)
DK (1) DK1434597T3 (sh)
EA (1) EA006881B1 (sh)
ES (1) ES2381341T3 (sh)
HR (1) HRP20040292A2 (sh)
IL (1) IL161310A0 (sh)
MX (1) MXPA04003442A (sh)
NO (1) NO20041908L (sh)
PL (1) PL369296A1 (sh)
WO (1) WO2003033015A1 (sh)
YU (1) YU29804A (sh)
ZA (1) ZA200402351B (sh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033015A1 (en) * 2001-10-11 2003-04-24 Applied Research Systems Ars Holding N.V. USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY
WO2004101617A1 (en) 2003-05-13 2004-11-25 Applied Research Systems Ars Holding N.V. Active variants of the il-18 binding protein and medical uses thereof
IL161672A0 (en) 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
AU2011203356B2 (en) * 2004-04-29 2012-03-22 Yeda Research & Development Co., Ltd IL6R/IL6 chimera for therapy of chemotherapy-induced peripheral neuropathy
IL161673A0 (en) * 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
IL163856A0 (en) * 2004-09-01 2005-12-18 Applied Research Systems Use of IL-6 in vascular complications
CA2681935A1 (en) * 2007-03-30 2008-10-09 Baker Medical Research Institute Treatment of obesity
DE102008057867A1 (de) * 2008-11-18 2010-05-20 B. Braun Melsungen Ag Fettemulsion zur künstlichen Ernährung von schwerkranken Intensivpatienten
CN106924736B (zh) * 2017-05-09 2020-01-03 北京师范大学 gp130抑制剂在制备干预和治疗肥胖导致的血糖代谢疾病产品中的应用
FR3080533A1 (fr) * 2018-04-27 2019-11-01 Enterosys Utilisation de l'il-6 pour le traitement du diabete

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849571A (en) * 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5300292A (en) * 1991-05-03 1994-04-05 The Regents Of The University Of California Composition and method for treating inflammation
IT1261787B (it) * 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
US6479258B1 (en) * 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US5741772A (en) * 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
WO2001003737A1 (en) 1999-07-13 2001-01-18 Bolder Biotechnology Inc. Immunoglobulin fusion proteins
WO2003033015A1 (en) * 2001-10-11 2003-04-24 Applied Research Systems Ars Holding N.V. USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY

Also Published As

Publication number Publication date
WO2003033015A1 (en) 2003-04-24
JP2005505608A (ja) 2005-02-24
DK1434597T3 (da) 2012-02-27
BR0213183A (pt) 2004-08-31
ZA200402351B (en) 2005-03-29
US20050058623A1 (en) 2005-03-17
US7465441B2 (en) 2008-12-16
MXPA04003442A (es) 2004-07-08
EA200400520A1 (ru) 2004-08-26
HRP20040292A2 (en) 2005-06-30
EP1434597A1 (en) 2004-07-07
CA2463020A1 (en) 2003-04-24
ATE542542T1 (de) 2012-02-15
CN1602203A (zh) 2005-03-30
AU2002340547B2 (en) 2008-04-03
US8278286B2 (en) 2012-10-02
PL369296A1 (en) 2005-04-18
YU29804A (sh) 2006-08-17
KR20050035151A (ko) 2005-04-15
IL161310A0 (en) 2004-09-27
US20100189684A1 (en) 2010-07-29
EA006881B1 (ru) 2006-04-28
ES2381341T3 (es) 2012-05-25
EP1434597B1 (en) 2012-01-25
US20090169506A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
HUP0301868A2 (hu) Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz
DK1411938T3 (da) Anvendelse af cyclopamin til fremstilling af et medikament til behandling af psoriasis
DE602005018763D1 (de) Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
BG66080B1 (bg) Заместени тиоацетамиди
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
MXPA05011266A (es) Metodos para el tratamiento de enfermedades relacionadas con la interleucina-6.
DE60234577D1 (de) Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält
NO20041908L (no) Anvendelse av gpl30 aktivatorer ved diabetisk neuropati
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
DK1117403T3 (da) MGLUR5-antagonister til behandling af smerte og angst
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
EE05357B1 (et) Tablett, mis sisaldab v„hemalt kahte eristatavat segmenti, ning selle kasutamine
DE60115054D1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
MXPA04001912A (es) Aminobenzofenonas novedosas.
EA200300639A1 (ru) Применение sarp-1 для лечения и/или предупреждения склеродермии
DE60110087D1 (de) Verwendung von Carboanhydrase-Inhibitoren zur Prävention von diabetischer Retinopathie bei Diabetikern
MXPA04001205A (es) Compuesto para eliminar y/o mitigar la anhedonia.
SE0101258D0 (sv) Treatment of low back pain and whiplash associated disorder
ATE444762T1 (de) Therapeutische zusammenseztungen zur toleranzinduktion
EA201000501A1 (ru) Фармацевтическая композиция, содержащая не обладающий нейротоксичностью активатор плазминоген для лечения удара
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
DE602005013572D1 (de) Cc-chemokin-antagonisten
DE60229624D1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
BR0211533A (pt) Tratamento de dor crÈnica com 3-heterociclil- e 3-cicloalquil-3-ariloxipropanaminas

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application